Company / Shareholders' Equity
Jazz Pharmaceuticals Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$4.3B
FY2025
5-year range
$3.1B / $4.3B
FY2021-FY2025
Trend
+5.5%
vs FY2024
Sector context
#21 of 213
Health Care
What the data says
Among 213 Health Care companies, Jazz Pharmaceuticals is in the top 10% for shareholders' equity. Shareholders' Equity has increased for 6 consecutive years, from $2.7B in FY2019 to $4.3B in FY2025.
Based on SEC 10-K filings.
$4.3B in FY2025 with a 5-year CAGR of +9.4%. Top quartile in the Health Care sector.
Improved from $3.7B to $4.3B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +5.7%
- 5-Year CAGR
- +9.4%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 213This company $4.3B Sector average $2.5B
▼
+69.5% above sector average
Key checks
Key Insights
- Jazz Pharmaceuticals's shareholders' equity has grown for 6 consecutive years.
- 5-year CAGR of +9.4%, indicating consistent growth.
- In FY2025, shareholders' equity increased 5.5% year-over-year.
- Ranks #21 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.3B | +5.5% |
| FY2024 | $4.1B | +9.5% |
| FY2023 | $3.7B | +2.1% |
| FY2022 | $3.7B | +17.6% |
| FY2021 | $3.1B | +12.8% |
| FY2020 | $2.8B | +1.6% |
| FY2019 | $2.7B | +0.0% |
| FY2018 | $2.7B | +0.0% |
| FY2017 | $2.7B | +97.9% |
| FY2016 | $1.4B | -14.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026